Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | VDR | P11473 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713939 | 0.86 | MAPT (0.44) | SLC6A3HSP90AA1MAPTHTTNPSR1 | |
| SCHEMBL385218 | 0.85 | ALDH1A1 (0.54) | SLC6A3HSP90AA1MAPTHTTNPSR1 | |
| SCHEMBL16598552 | 0.85 | ALDH1A1 (0.45) | SLC6A3HSP90AA1MAPTHTTNPSR1 | |
| SCHEMBL17859341 | 0.83 | LMNA (0.60) | MAPTHTTALDH1A1TSHRKMT2A | |
| SCHEMBL6776012 | 0.83 | SLC6A3 (0.50) | SLC6A3HSP90AA1MAPTHTTNPSR1 | |
| SCHEMBL21505718 | 0.83 | SLC6A3 (0.50) | SLC6A3HSP90AA1MAPTHTTNPSR1 | |
| SCHEMBL6042447 | 0.83 | SLC6A3 (0.50) | SLC6A3HSP90AA1MAPTHTTNPSR1 | |
| SCHEMBL16836611 | 0.81 | ALDH1A1 (0.59) | MAPTHTTALDH1A1TSHRKMT2A | |
| SCHEMBL27413245 | 0.81 | HSP90AA1 (0.57) | SLC6A3HSP90AA1MAPTHTTNPSR1 | |
| SCHEMBL19564484 | 0.81 | ABCB1 (0.46) | HTTALDH1A1TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9994570-B2 | Bridged diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994570-B2 | Bridged diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994570-B2 | Bridged diazepane orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9938276-B2 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| WO-2016086357-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016089721-A1 | METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016085783-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016085783-A1 | BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016069517-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065585-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| CN-103857657-B | Hete rocyclic derivatives and medicine | NIPPON SHINYAKU CO.,LTD. (JP) | 2016-04-20 | — | — | CN | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| CN-103857657-A | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINYAKU CO LTD | 2014-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | HCRTR1, HCRTR2, OXTR | SLC6A3 513/4885HSP90AA1 1908/4885MAPT 1009/4885 |
| US-10011595-B2 | Ethyldiamine orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | SLC6A3 221/4885HSP90AA1 3812/4885MAPT 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.